GRM7 and Cognitive impairment: It has been suggested mGlu7 may represent a new treatment target for neurodevelopmental disorders [134], and current neurochemical and behavioral findings certainly appear to justify continued preclinical evaluation of mGlu7 allosteric antagonists against a broader variety of PCP-Iso-induced cognitive impairments.